Abingworth’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Abingworth’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.95M	Hold	1,041,131	–	–	0.63%	14
2022 Q3	$2.68M	Hold	1,041,131	–	–	0.91%	11
2022 Q2	$2M	Hold	1,041,131	–	–	0.64%	14
2022 Q1	$3.08M	Hold	1,041,131	–	–	0.87%	14
2021 Q4	$4.65M	Hold	1,041,131	–	–	1.13%	13
2021 Q3	$5.06M	Hold	1,041,131	–	–	1.15%	15
2021 Q2	$7.09M	Hold	1,041,131	–	–	2.19%	13
2021 Q1	$7.33M	Hold	1,041,131	–	–	2.53%	11
2020 Q4	$6.52M	Hold	1,041,131	–	–	2.23%	10
2020 Q3	$5.62M	Hold	1,041,131	–	–	1.2%	11
2020 Q2	$5.42M	Hold	1,041,131	–	–	1.52%	9
2020 Q1	$3.24M	Hold	1,041,131	–	–	2.15%	9
2019 Q4	$4.18M	Hold	1,041,131	–	–	2.02%	8
2019 Q3	$4.51M	Hold	1,041,131	–	–	2.85%	6
2019 Q2	$4.12M	Hold	1,041,131	–	–	1.58%	7
2019 Q1	$5.59M	Hold	1,041,131	–	–	5%	6
2018 Q4	$5.34M	Hold	1,041,131	–	–	4.85%	7
2018 Q3	$10M	Hold	1,041,131	–	–	5.97%	4
2018 Q2	$10.6M	Hold	1,041,131	–	–	6.04%	3
2018 Q1	$13.5M	Hold	1,041,131	–	–	8.41%	3
2017 Q4	$18.6M	Hold	1,041,131	–	–	13.5%	3
2017 Q3	$26.1M	Sell	1,041,131 -259,301	-20%	-$6.04M	18.09%	3
2017 Q2	$31.3M	Sell	1,300,432 -981	-0.1%	-$21.7K	24.89%	2
2017 Q1	$25.1M	Hold	1,301,413	–	–	18.67%	2
2016 Q4	$20M	Hold	1,301,413	–	–	16.7%	2
2016 Q3	$16.9M	Hold	1,301,413	–	–	16.22%	3
2016 Q2	$18.1M	Hold	1,301,413	–	–	18.96%	1
2016 Q1	$19.7M	Hold	1,301,413	–	–	18.31%	1
2015 Q4	$24.7M	Hold	1,301,413	–	–	14.9%	3
2015 Q3	$24.7M	Hold	1,301,413	–	–	14.43%	3
2015 Q2	$33.5M	Hold	1,301,413	–	–	15.21%	3
2015 Q1	$40.1M	Hold	1,301,413	–	–	17.03%	2
2014 Q4	$50M	Buy	+1,301,413	New	+$31.1M	14.19%	2

Other funds holding PRTK

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Abingworth's PRTK Position: Q4 2022 in Review

Abingworth held its Paratek Pharmaceuticals, Inc. (PRTK) position steady in Q4 2022 at 1,041,131 shares worth $1.95M. The position accounts for 0.63% of the portfolio, ranked #14.

Abingworth first reported a position in PRTK in Q4 2014 and has held it in 33 quarters since. The position peaked at $50M in Q4 2014. 76 funds tracked by Wall St. Rank hold PRTK as of Q4 2022.

Abingworth held 1,041,131 shares of Paratek Pharmaceuticals, Inc. worth $1.95M as of Q4 2022.
Abingworth left its Paratek Pharmaceuticals, Inc. share count unchanged in Q4 2022.
Paratek Pharmaceuticals, Inc. made up 0.63% of Abingworth's portfolio in Q4 2022, its #14 holding.
Abingworth first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and has held it in 33 quarters since.
Abingworth's Paratek Pharmaceuticals, Inc. position peaked at $50M in Q4 2014.
76 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.